Long-acting amylin receptor agonists and uses thereof
The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and/or chronic weight management, dyslipidemia and/or NASH. The disclosure relates to compounds that agonize the amylin receptor and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity, and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.
1 . A compound comprising a sequence selected from the group consisting of SEQ ID NO: 22, SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:25, or a pharmaceutically acceptable salt thereof.
2 . The compound of claim 1 comprising SEQ ID NO:22.
3 . The compound of claim 1 comprising SEQ ID NO:23.
4 . The compound of claim 1 comprising SEQ ID NO:24.
5 . The compound of claim 1 comprising SEQ ID NO:25.
6 . The compound of claim 1 wherein there is a thioacetal bridge between the cysteines at positions 2 and 7.
7 . The compound of claim 2 wherein the compound comprises:
8 . The compound of claim 1 wherein there is a disulfide bridge between the cysteines at positions 2 and 7.
9 . A method of treating a condition in a patient in need thereof, comprising administering to the patient an effective amount of a compound comprising a sequence selected from the group consisting of SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:25, or a pharmaceutically acceptable salt thereof, wherein the condition is selected from the group consisting of diabetes, obesity, NASH, and dyslipidemia.
10 . The method of claim 9 wherein the condition is diabetes.
11 . The method of claim 9 wherein the condition is obesity.
12 . The method of claim 9 wherein the condition is NASH.
13 . The method of claim 9 wherein the condition is dyslipidemia.
14 . The method of claim 9 further comprising administering to the patient an effective amount of an additional agent.
15 . A method of lowering food intake, body weight, blood glucose, or triglycerides, in a patient in need thereof, comprising administering to the patient an effective amount of a compound comprising a sequence selected from the group consisting of SEQ ID NO:22, SEQ ID NO: 23, SEQ ID NO:24, and SEQ ID NO:25, or a pharmaceutically acceptable salt thereof.
16 . The method of claim 15 further comprising administering to the patient an effective amount of an additional agent.
17 . The method of claim 16 wherein the additional agent is an incretin or incretin analog.
18 . The method of claim 17 wherein the incretin or incretin analog is a compound comprising SEQ ID NO:21.